Stephen A Sherwin insider trades

Open-market stock purchases and sales by Stephen A Sherwin, Director at Neurocrine Biosciences Inc, from SEC Form 4 filings since Mar 22, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -57%.

Recent trades

DateStockTradeValue
Sep 2, 2026NBIX Neurocrine Biosciences IncSold (not open market)—
Jun 9, 2026BIIB Biogen IncBought (not open market)—
Jun 5, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Jun 5, 2026NBIX Neurocrine Biosciences IncSold$1.3M
Jun 5, 2026NBIX Neurocrine Biosciences IncSold$419K
Jun 5, 2026NBIX Neurocrine Biosciences IncSold$1.1M
Jun 5, 2026NBIX Neurocrine Biosciences IncSold$971K
Jun 5, 2026NBIX Neurocrine Biosciences IncSold$308K
Jun 5, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
May 27, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
May 21, 2026NBIX Neurocrine Biosciences IncBought (not open market)—

Companies traded

  • NBIX Neurocrine Biosciences Inc: 12 sales, last Sep 2, 2026
  • BIIB Biogen Inc: 12 sales, last Jun 9, 2026
  • NTGN Neon Therapeutics, Inc: other filings, last May 6, 2020
  • ADRO Aduro Biotech, Inc: other filings, last May 5, 2020
  • RIGL Rigel Pharmaceuticals Inc: other filings, last May 11, 2016
  • VSTM Verastem, Inc: 1 buy, last Jun 12, 2015
  • VICL Vical Inc: 1 buy, last May 21, 2015
  • BPAX Biosante Pharmaceuticals Inc: other filings, last Mar 30, 2012

Get free alerts when Stephen A Sherwin files a new trade →